280 related articles for article (PubMed ID: 28066751)
21. Synthesis and Biological Activity of Scyllatoxin-Based BH3 Domain Mimetics Containing Two Disulfide Linkages.
Arachchige D; Holub JM
Protein J; 2018 Oct; 37(5):428-443. PubMed ID: 30128635
[TBL] [Abstract][Full Text] [Related]
22. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
23. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
24. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
25. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide.
Hadji A; Schmitt GK; Schnorenberg MR; Roach L; Hickey CM; Leak LB; Tirrell MV; LaBelle JL
Oncotarget; 2019 Oct; 10(58):6219-6233. PubMed ID: 31692812
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis in the development and maintenance of the immune system.
Opferman JT; Korsmeyer SJ
Nat Immunol; 2003 May; 4(5):410-5. PubMed ID: 12719730
[TBL] [Abstract][Full Text] [Related]
27. Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells.
Skommer J; Das SC; Nair A; Brittain T; Raychaudhuri S
Apoptosis; 2011 Jun; 16(6):619-26. PubMed ID: 21442307
[TBL] [Abstract][Full Text] [Related]
28. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
[TBL] [Abstract][Full Text] [Related]
29. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.
Goldsmith KC; Liu X; Dam V; Morgan BT; Shabbout M; Cnaan A; Letai A; Korsmeyer SJ; Hogarty MD
Oncogene; 2006 Aug; 25(33):4525-33. PubMed ID: 16568093
[TBL] [Abstract][Full Text] [Related]
30. Activating the Intrinsic Pathway of Apoptosis Using BIM BH3 Peptides Delivered by Peptide Amphiphiles with Endosomal Release.
Schnorenberg MR; Bellairs JA; Samaeekia R; Acar H; Tirrell MV; LaBelle JL
Materials (Basel); 2019 Aug; 12(16):. PubMed ID: 31408950
[TBL] [Abstract][Full Text] [Related]
31. The BCL-2 protein family, BH3-mimetics and cancer therapy.
Delbridge AR; Strasser A
Cell Death Differ; 2015 Jul; 22(7):1071-80. PubMed ID: 25952548
[TBL] [Abstract][Full Text] [Related]
32. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
33. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
34. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
35. Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents.
Ralph SJ; Low P; Dong L; Lawen A; Neuzil J
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):327-46. PubMed ID: 18221044
[TBL] [Abstract][Full Text] [Related]
36. BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.
Letai A
Expert Opin Biol Ther; 2003 Apr; 3(2):293-304. PubMed ID: 12662143
[TBL] [Abstract][Full Text] [Related]
37. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
38. Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia.
Besbes S; Mirshahi M; Pocard M; Billard C
Blood Rev; 2015 Sep; 29(5):345-50. PubMed ID: 25887155
[TBL] [Abstract][Full Text] [Related]
39. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
40. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
